VANDA PHARMACEUTICALS INC's ticker is VNDA and the CUSIP is 921659108. A total of 132 filers reported holding VANDA PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 2.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $51,098,000 | -34.8% | 3,626,545 | -14.8% | 3.62% | -26.9% |
| Q1 2019 | $78,354,000 | -35.6% | 4,258,358 | -8.6% | 4.95% | -44.8% |
| Q4 2018 | $121,733,000 | +19.4% | 4,658,759 | +4.8% | 8.95% | +63.0% |
| Q3 2018 | $101,984,000 | +16.2% | 4,443,759 | -3.6% | 5.49% | -3.0% |
| Q2 2018 | $87,802,000 | +69.6% | 4,609,043 | +50.0% | 5.66% | +19.7% |
| Q1 2018 | $51,768,000 | +408.4% | 3,072,275 | +180.9% | 4.73% | +246.3% |
| Q4 2015 | $10,182,000 | -37.2% | 1,093,696 | -23.9% | 1.37% | -40.1% |
| Q3 2015 | $16,207,000 | -18.7% | 1,436,796 | +17.1% | 2.28% | -23.1% |
| Q1 2014 | $19,935,000 | +1444.2% | 1,226,772 | +1079.6% | 2.97% | +1299.1% |
| Q4 2013 | $1,291,000 | -76.8% | 104,000 | -79.5% | 0.21% | -84.7% |
| Q3 2013 | $5,557,000 | -51.9% | 507,469 | -64.5% | 1.39% | -66.2% |
| Q2 2013 | $11,553,000 | – | 1,429,798 | – | 4.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,010,000 | $32,060,000 | 6.59% |
| Palo Alto Investors LP | 4,203,270 | $67,042,000 | 3.82% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,424,676 | $54,624,000 | 2.25% |
| ARMISTICE CAPITAL, LLC | 580,000 | $9,251,000 | 2.19% |
| Avoro Capital Advisors LLC | 381,466 | $6,084,000 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 135,817 | $2,166,000 | 0.98% |
| ACUTA CAPITAL PARTNERS, LLC | 162,600 | $2,593,000 | 0.96% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 450,847 | $7,191,000 | 0.50% |
| Cheyne Capital Management (UK) LLP | 52,000 | $831,000 | 0.47% |
| OXFORD ASSET MANAGEMENT LLP | 757,507 | $12,082,000 | 0.43% |